A single center randomized double blind controlled trial of pentoxifylline in acute pancreatitis: Challenges and opportunities.

ABSTRACT:

Objectives

Despite substantial morbidity and mortality associated with acute pancreatitis (AP), only one small randomized controlled drug trial (RCT) is available in the past few decades from the United States. Hence, we conducted a single-center, double-blind, placebo-controlled RCT of pentoxifylline in AP.

Methods

A total of 9 doses of oral pentoxifylline 400 mg or placebo tablet, three times daily, was administered within 72 h of diagnosis, using randomization blocks by pharmacy. Primary outcome was a composite outcome including any of the following: death, peripancreatic and/or pancreatic necrosis, infected pancreatic necrosis, persistent organ failure, persistent systemic inflammatory response syndrome, hospital stay longer than 4 days, need for intensive care, and need

SUBMITTER: Vege SS 

PROVIDER: S-EPMC7704646 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature